GCAN 101

Drug Profile

GCAN 101

Alternative Names: GCAN101

Latest Information Update: 13 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GammaCan International
  • Class Antineoplastics; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Dec 2005 GammaCan has entered into a research and licensing agreement with Tel Hashomer Medical Research Infrastructure and Services Ltd
  • 27 Jul 2005 Phase-II clinical trials in Cancer in Israel (IV)
  • 17 Mar 2005 Preclinical trials in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top